MedTrace Logo

Biomarker Levels as A Predictor of Concussion Severity OUTcomes (BlacOut)

NCT02992327 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2018-09-07

No results posted yet for this study

Summary

The overall research aim of this pilot study is to determine if the structural brain protein calpain-cleaved αII-spectrin N-terminal fragment (SNTF) can be used as a blood biomarker to accurately identify patients who will have more severe symptoms and reduced neurocognitive functioning after sustaining a concussion. Concussion is also referred to as mild traumatic brain injury (mTBI) in the literature. Both terms will be used interchangeably throughout this application.

Conditions

  • Concussion, Mild
  • Neurocognitive Dysfunction

Sponsors & Collaborators

Principal Investigators

  • Sandi Wewerka, MPH · Regions Hospital

Eligibility

Min Age
8 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-30
Primary Completion
2018-08-06
Completion
2018-08-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02992327 on ClinicalTrials.gov